The impact of advanced age according to IPSSWM cut-off on the outcome of symptomatic and asymptomatic Waldenström's macroglobulinemia at diagnosis

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 1, 2011, Pages 124-126

  Ricci, F ^a,c   Tedeschi, A ^a   Vismara, E ^a   Greco, A ^d   Montillo, M ^a   Nichelatti, M ^a   Varettoni, M ^b   Lazzarino, M ^b   Morra, E ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; BENCE JONES PROTEIN; BETA 2 MICROGLOBULIN; CREATININE; HEMOGLOBIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN M; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGING; BONE MARROW; CELL INFILTRATION; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; CREATININE BLOOD LEVEL; DEATH; DISEASE SPECIFIC SURVIVAL; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HEPATITIS C; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIGHT CHAIN; LYMPHADENOPATHY; NEUROPATHY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; RETROSPECTIVE STUDY; STATISTICAL MODEL; SURVIVAL; THROMBOCYTE COUNT; TREATMENT FREE SURVIVAL; WALDENSTROEM MACROGLOBULINEMIA;

EID: 79953720004     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2011.n.027     Document Type: Conference Paper

References (13)

1. Dimopoulos MA, Panayiotidis P, Moulopoulos LA, et al. Waldenström's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000; 18:214-26
2. Facon T, Brouillard M, Duhamel A, et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993; 11:1553-8. (Pubitemid 23228262)
3. Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96:852-8. (Pubitemid 30616846)
4. Merlini G, Baldini L, Broglia C, et al. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30:211-5. (Pubitemid 36506311)
5. Garcia-Sanz R, Montoto S, Torrequebrada A, et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115:575-82. (Pubitemid 34019184)
6. Gobbi PG, Bettini R, Montecucco C, et al. Study of prognosis in Waldenstrom's macroglobulinemia: a proposal for a simple binary classification with clinical and investigational utility. Blood 1994; 83:2939-45.
7. Morel P, Monconduit M, Jacomy D, et al. Prognostic factors in Waldenstrom's macroglobulinemia: a report on 232 patients with the description of a new scoring system and its validation on 253 other patients. Blood 2000; 96:852-8. (Pubitemid 30616846)
8. Owen RG, Barrans SL, Richards SJ, et al. Waldenstrom macroglobulinemia: development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol 2001; 116:420-8. (Pubitemid 32851976)
9. Dimopoulos MA, Hamilos G, Zervas K, et al. Survival and prognostic factors after initiation of treatment in Waldenstrom's macroglobulinemia. Ann Oncol 2003; 14:1299-305. (Pubitemid 37039059)
10. Dhodapkar MV, Jacobson JL, Gertz MA, et al. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).Semin Oncol 2003; 30:220-5. (Pubitemid 36506313)
11. Ghobrial IM, Fonseca R, Gertz MA, et al. Prognostic model for disease-specific and overall mortality in newly diagnosed symptomatic patients with Waldenstrom macroglobulinaemia. Br J Haematol 2006; 133:158-64.
12. Kastritis E, Zervas K, Repoussis P, et al. Prognostication in young and old patients with Waldenström's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. Clin Lymphoma Myeloma 2009; 9:50-2.
13. Mátrai Z, Németh J, Miklós K, et al. Serum bet2-microglobulin measured by immunonephelometry: expression patterns and reference intervals in healthy adults. Clin Chem Lab Med 2009; 47:585-9.